NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
NBSE
Delisted
NBSE was delisted on the 10th of May, 2024.
45 hedge funds and large institutions have $31.6M invested in NeuBase Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
less first-time investments, than exits
New positions opened: | Existing positions closed:
76% less call options, than puts
Call options by funds: $12K | Put options by funds: $51K
Holders
45
Holding in Top 10
1
Calls
$12K
Puts
$51K
Top Buyers
| 1 | +$2.81M | |
| 2 | +$644K | |
| 3 | +$211K | |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$104K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$83K |
Top Sellers
| 1 | -$1.27M | |
| 2 | -$756K | |
| 3 | -$396K | |
| 4 |
Two Sigma Advisers
New York
|
-$391K |
| 5 |
Two Sigma Investments
New York
|
-$310K |